GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RAPT Therapeutics Inc (FRA:0RA) » Definitions » 14-Day RSI

RAPT Therapeutics (FRA:0RA) 14-Day RSI : 69.70 (As of Dec. 12, 2024)


View and export this data going back to 2019. Start your Free Trial

What is RAPT Therapeutics 14-Day RSI?

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.

As of today (2024-12-12), RAPT Therapeutics's 14-Day RSI is 69.70.

The industry rank for RAPT Therapeutics's 14-Day RSI or its related term are showing as below:

FRA:0RA's 14-Day RSI is ranked better than
77.81% of 1523 companies
in the Biotechnology industry
Industry Median: 46.95 vs FRA:0RA: 69.70

Competitive Comparison of RAPT Therapeutics's 14-Day RSI

For the Biotechnology subindustry, RAPT Therapeutics's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


RAPT Therapeutics's 14-Day RSI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, RAPT Therapeutics's 14-Day RSI distribution charts can be found below:

* The bar in red indicates where RAPT Therapeutics's 14-Day RSI falls into.



RAPT Therapeutics  (FRA:0RA) 14-Day RSI Calculation

The formula for calculating RSI is:

RSI=100[ 100 / ( 1 + Average Gain / Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


RAPT Therapeutics  (FRA:0RA) 14-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.


RAPT Therapeutics 14-Day RSI Related Terms

Thank you for viewing the detailed overview of RAPT Therapeutics's 14-Day RSI provided by GuruFocus.com. Please click on the following links to see related term pages.


RAPT Therapeutics Business Description

Traded in Other Exchanges
Address
561 Eccles Avenue, South San Francisco, CA, USA, 94080
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.

RAPT Therapeutics Headlines

No Headlines